APF 2024: Shifting Paradigms in the Women’s Health Conversation

Only in the last decade has the global community started to tackle inequities for women in healthcare, from equal representation in clinical trials to reduced mortality. This increased focus is a welcome step toward innovation that moves beyond male biology as a ‘norm’— yet a one-size-fits-all approach misses the mark when it comes to representation of diverse populations. At the MDIC Annual Public Forum experts in women’s health convened to discuss these persisting inequities in health and to share visions of potential pathways to more targeted, effective, and equitable care.

MDIC In the News: SRS Initiative Update

Following a meeting at the MDIC Annual Public Forum, Maryellen de Mars, MDIC’s program director of clinical diagnostics, said in an interview that the consortium’s Somatic Reference Samples Initiative recently confirmed that it has successfully engineered the 10 target reference lines and is ready to start its next steps to confirm its results and establish use cases.

MDIC In the News: Andy Fish on Driving Positive Change in the Medtech Ecosystem

Following a meeting at the MDIC Annual Public Forum, Maryellen de Mars, MDIC’s program director of clinical diagnostics, said in an interview that the consortium’s Somatic Reference Samples Initiative recently confirmed that it has successfully engineered the 10 target reference lines and is ready to start its next steps to confirm its results and establish use cases.

Freespira’s Strategic Approach to Market Access

Freespira, Inc. developed an innovative digital therapeutic treatment to address the need for accessible and effective solutions for panic disorder, panic attacks, and post-traumatic stress disorder (PTSD). As the first FDA-cleared, medication-free, at-home treatment, Freespira stands out in the crowded landscape of digital therapeutics, overcoming the limitations of traditional treatments.

Insights from the MDIC Excellence in Quality Summit

The MDIC Excellence in Quality Summit brought together industry leaders, regulatory authorities, and quality professionals, all committed to advancing quality practices throughout the medical device lifecycle. Over two days, the Summit explored innovative strategies and shared insights that emphasized the critical importance of integrating a culture of quality within organizations, harnessing advanced technologies, and continually striving for improvement.

A Decade of Innovation in Medical Device Testing

Since its inception, the EFS program has supported device innovation and increased patient access to potentially beneficial new technologies. EFS allow investigators to gain early clinical experience with investigational devices, often to address unmet clinical needs, while incorporating enhanced risk mitigation strategies to protect patients.

NESTcc Partners with Booz Allen Hamilton for Active Surveillance in Medical Devices

NEST selects Booz Allen Hamilton to partner on the design and implementation of an active surveillance system using electronic health data to better understand the safety of medical devices as used within clinical practice.